There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Lantheus (LNTH – Research Report) and Evolent Health (EVH – Research Report) with bullish sentiments.
Lantheus (LNTH)
In a report released today, David Turkaly from JMP Securities reiterated a Buy rating on Lantheus, with a price target of $100.00. The company’s shares closed last Thursday at $65.05.
According to TipRanks.com, Turkaly is a 1-star analyst with an average return of
Currently, the analyst consensus on Lantheus is a Strong Buy with an average price target of $96.44, representing a 53.1% upside. In a report issued on February 14, Leerink Partners also maintained a Buy rating on the stock with a $96.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Evolent Health (EVH)
In a report released today, Constantine Davides from JMP Securities reiterated a Buy rating on Evolent Health, with a price target of $38.00. The company’s shares closed last Thursday at $29.77.
According to TipRanks.com, Davides has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Evolent Health with a $44.86 average price target, a 50.1% upside from current levels. In a report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $63.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on LNTH:
- Lantheus Reports Fourth Quarter and Full Year 2023 Financial Results
- Is LNTH a Buy, Before Earnings?
- Lantheus announces collaboration with NIA-sponsored study called CLARiTI
- Lantheus announces collaboration with a NIA-sponsored study called CLARiTT
- Lantheus Announces Collaboration to Provide Novel Tau Imaging Agent for Large Consortium Clinical Trial Sponsored by the National Institute on Aging
